Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high‐risk neuroblastoma

Carroll, Catherine; Clinton, Frieda; Smith, Aisling; Fox, Áine; Capra, Michael; Pears, Jane; Owens, Cormac

doi:10.1002/pbc.27386

Cited by 8 publications

(5 citation statements)

References 16 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PeNAT has been used to measure nausea severity in several pediatric studies (Carroll et al, 2018; Flank, Nadeem, Khanna et al, 2017; Flank et al, 2018; Flank, Sparavalo, Vol et al, 2017; Kovacevic et al, 2019). All were restricted to English-speaking patients and families.…”

Section: Discussionmentioning

confidence: 99%

Translation of the Pediatric Nausea Assessment Tool (PeNAT) Into Spanish and Evaluating Understandability Among Spanish-Speaking Hispanic American Children and Adolescents Receiving Chemotherapy

Frausto

Sivananthan

Golden

et al. 2021

Hisp Health Care Int

View full text Add to dashboard Cite

Introduction: We aimed to create a Spanish-language version of the Pediatric Nausea Assessment Tool (PeNAT) and examine its understandability among Spanish-speaking, Hispanic American children. Methods: Translation: Forward and backward translations of the PeNAT documents were performed and verified by a bilingual panel. Four monolingual, Spanish-speaking dyads (child/parent) and four bilingual dyads piloted the Spanish-language PeNAT documents. Four additional bilingual dyads read both versions and completed the PeNAT using their preferred version. These were reviewed for errors due to misunderstanding. Understandability: Children aged 4–18 years about to receive chemotherapy who spoke Spanish at home and were without impairments precluding PeNAT use were eligible. Participants used the Spanish-language PeNAT during a chemotherapy block. Parents gave feedback on the PeNAT documents. Recruitment continued until 10 consecutive participants offered no substantive suggestions for revision. Results: Translation: All child/parent dyads completed the PeNAT without errors attributable to misunderstanding. The Spanish-language PeNAT was preferred by three of four bilingual dyads. Understandability: Ten cancer patients (mean age: 10.6 years) used the Spanish-language PeNAT. All parents felt their child understood the PeNAT; none felt the documents were hard or very hard to use. Conclusion: The Spanish-language PeNAT was understood by Spanish-speaking Hispanic American children. Further psychometric testing is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Translation of the Pediatric Nausea Assessment Tool (PeNAT) Into Spanish and Evaluating Understandability Among Spanish-Speaking Hispanic American Children and Adolescents Receiving Chemotherapy

Frausto

Sivananthan

Golden

et al. 2021

Hisp Health Care Int

View full text Add to dashboard Cite

show abstract

“…Our study emphasises again the need to rigorously adhere to antiemetic prophylaxis strategies during chemotherapy. Undertaking this would improve acute control 8 as well as anticipatory, and potentially other side effects such as weight loss and febrile episodes 9 .…”

Section: Discussionmentioning

confidence: 99%

Prevalence of anticipatory nausea and vomiting in children undergoing cytotoxic chemotherapy for malignant disease - the SiCK2 (Sickness prior to Chemotherapy in Kids) study

Phillips

ffrench-Devitt

Wellings³

2020

Preprint

View full text Add to dashboard Cite

Introduction Anticipatory nausea and vomiting (ANV) is thought to be a conditioned response to nausea and vomiting experienced in previous chemotherapy cycles, and has a significant negative impact on quality of life for children having treatment for cancer. The prevalence of this aversive experience with current antiemetics remains uncertain. Methods Self-report questionnaires completed by patients and parents across seven sites in the UK. Nausea and vomiting symptoms 24 hours prior to commencing chemotherapy were assessed with the Pediatric Nausea Assessment Tool (PeNAT). Data were also collected on the patients' age, sex, oncological diagnosis, and previous experience of chemotherapy induced nausea and vomiting. Correlation between demographic data, chemotherapy information and prior reported experience of chemotherapy related nausea and vomiting was undertaken using multiple ordinal regression. Results 191 episodes of anticipatory nausea and vomiting status were returned. 34% of patients described severe or very severe anticipatory nausea and/or vomiting. The severity of anticipatory nausea and vomiting was predicted two factors related to prior chemotherapy: control of anticipatory (OR 0.23 95%CI 0.09 to 0.53) and acute/delayed (OR 0.37, 95% CI 0.16 to 0.83) nausea and vomiting, and one current factor, the administration of antiemetic medication prior to arrival at the hospital (OR 3.0, 95%CI 1.3 to 6.8). Conclusions This study re-enforces, disappointingly, the continued high prevalence of anticipatory nausea and vomiting in children about to receive chemotherapy. There is clearly a need to improve interventions for this rarely discussed aversive experience of childhood cancer. Its high prevalence suggests trials of interventions should be possible to power effectively, and develop interventions that are both acceptable and deliverable.

show abstract

“…Таким образом, для возможности адекватной оценки ТИР в детской популяции несомненную роль играют специализированные шкалы. Стандартизированные шкалы BARF и PeNAT показали свою эффективность как в ряде крупных педиатрических исследований [22][23][24][25][26], так и в нашем исследовании. Однако помимо вышеописанных шкал нельзя не отметить и практическую значимость модифицированного опросника.…”

Section: Drug Dosesunclassified

The chemotherapy-induced nausea and vomiting in children and adolescents receiving highly emetogenic chemotherapy. Hidden problem

Rabaeva

Жуков

2022

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

Introduction. Despite significant advances in prevention, chemotherapy-induced (cytostatic therapy) nausea and vomiting (CINV) continues present a significant clinical problem for patients oncohematological profile, while often remaining outside areas of attention of pediatric oncologists and hematologists.The aim of the study – frequency comparison of occurrence CINV according to data obtained from the medical database documentation (retrospective group) and data obtained in the process assessment of CINV using a modified questionnaire and specialized scales (prospective group).Materials and methods. The retrospective group included 52 patients who received 178 cycles of highly emetogenic anticancer therapy with standard antiemetic prophylaxis from 02/01/2020 to 08/01/2020, in prospective – 88 patients who received 456 cycles of a similar anticancer therapy with standard CINV prophylaxis from 10/01/2020 until 07/01/2021.Results. Although the groups were comparable in terms of key patient characteristics, chemotherapy regimens, and regimen prevention of CINV, the frequency of complete control of CINV between them is significantly was different: when analyzing the primary documentation, it turned out that the complete control of CINV in the acute, delayed and general periods is observed in 82 %, 86 %, 82 % cycles, while when assessing CINV using specialized questionnaires, the absence of these complications was noted only in 68 %, 52 %, 43 % of cycles. Thus, if we focus on standard tools fixing complications (diary entries, prescription lists), in more than 80 % of children receiving highly emetogenic cytostatic therapy it is possible to achieve complete control of CINV, and this complication does not really pose a clinically significant problem. However, when using a questionnaire and specialized scales, it becomes obvious that that more than half of children continue to suffer from CINV despite the standard prophylaxis of this complication.Conclusion. In this way, the analysis performed shows that the frequency of development of CINV during routine antiemetic prophylaxis is clearly underestimated, and, in part, due to this CINV and remains outside the attention of pediatric oncologists and hematologists. For an adequate assessment of the true incidence of CINV and, accordingly, determining the need for improvement of existing approaches to their prevention, a key role should be played specialized questionnaires and scales that fully allow “visualize” this complication.

show abstract

Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high‐risk neuroblastoma

Cited by 8 publications

References 16 publications

Translation of the Pediatric Nausea Assessment Tool (PeNAT) Into Spanish and Evaluating Understandability Among Spanish-Speaking Hispanic American Children and Adolescents Receiving Chemotherapy

Translation of the Pediatric Nausea Assessment Tool (PeNAT) Into Spanish and Evaluating Understandability Among Spanish-Speaking Hispanic American Children and Adolescents Receiving Chemotherapy

Prevalence of anticipatory nausea and vomiting in children undergoing cytotoxic chemotherapy for malignant disease - the SiCK2 (Sickness prior to Chemotherapy in Kids) study

The chemotherapy-induced nausea and vomiting in children and adolescents receiving highly emetogenic chemotherapy. Hidden problem

Contact Info

Product

Resources

About